Will the North Carolina PFAS bellwether trial return an adverse verdict against Chemours by 2026-09-30?

Industry base rate for first-bellwether plaintiff wins in mass tort chemicals/pharma runs 50-70%, but strict resolution criteria impose timing and procedural discounts. The question requires: (a) trial reaches verdict by 9/30/2026 (~75-80% conditional), (b) plaintiff win on liability (~55-65% conditional), and (c) not settled without adverse liability disclosure. Joint probability is approximately 0.78 x 0.60 x 0.85 = 0.40 before further adjustment. Adjust down for Chemours' high-quality defense counsel and the possibility that an adverse outcome would be settled with non-adverse-liability framing. Lands at 0.34.

The committee flagged that bellwether selection bias matters and could not determine whether NC is plaintiff-selected (favors plaintiff) or mutually-selected (more symmetric). Under uncertainty, weight outcomes symmetrically: ~50% plaintiff win given reaching verdict. Probability of reaching verdict by 9/30/2026 is ~75%. Probability of resolution with clean adverse-liability finding (not settled quietly, not ambiguous split verdict) is ~80%. Joint: 0.75 x 0.50 x 0.80 = 0.30. This aligns with historical base rates for 'cleanly adverse verdict' in strict-criteria resolution.

Asbestos base rate analogy from Black Swan Beacon is instructive: mass torts historically produce adverse first-bellwether outcomes at above-random rates because plaintiff counsel selects for strong cases and public record (EPA consent orders, decades of internal documents for DuPont/Chemours) supports liability findings. Adjust upward from symmetric 30% to 35%. Compound scenario correlation (RICO denial would increase NC adverse probability) is relevant but RICO resolution unlikely to precede NC verdict in timeline. Net 0.35.

Three-stage decision tree: trial reaches verdict (~75-80%), jury finds for plaintiff (~55%), outcome cleanly adverse not settled/ambiguous (~80%). Joint approximately 0.78 x 0.55 x 0.80 = 0.34. Slight downward adjustment for (a) possibility of mid-trial settlement that is disclosed as neutral, (b) DuPont MOU cost-sharing dynamic means any settlement absorbs cost-sharing and may not be disclosed as adverse. Settles at 0.32.

The resolution criteria are strict — requires 'plaintiff win' not just unfavorable process outcomes. Meaningful downward adjustment: (a) bellwethers settle before verdict ~30% of the time; these settlements often are not disclosed as adverse liability, (b) split verdicts on liability vs damages may be ambiguous, (c) jury verdicts can be appealed and stayed pre-disclosure. Probability of strictly-defined YES (clean plaintiff verdict by 9/30/2026) is 0.28.

Balanced view: mass tort base rate tilts toward 50-55% plaintiff win given reaching verdict, but strict criteria + timing + settlement risk compress to ~0.30-0.35. Chemours' 44% YTD rally reflects market dismissal of this risk, which is itself a mild signal that sophisticated observers are weighting low adverse probability. However, the market has been wrong on PFAS tail pricing per Myth Meter. Net 0.33.

PFAS MDL bellwether with plaintiff-friendly factual record (DuPont internal documents, EPA precedent) has above-symmetric adverse probability conditional on verdict. Timing and settlement filters compress to 0.30. Pure base-rate anchor.

Three-factor product: 75% reaches verdict, 55% plaintiff win, 75% cleanly-adverse. Joint 0.31. Slight upward adjustment for PFAS-specific factual record. Net 0.32.

Base rate 50-60% for plaintiff wins in first PFAS bellwether conditional on reaching verdict, discounted 65-70% for timing and settlement filters, gives 0.30-0.35. Settle near middle at 0.33.